Waf1/Cip1 is among the most important mediators of the tumor suppressor p53. However, there is increasing evidence indicating that p21 could favor tumorigenesis in specific cell types. In particular, the absence of p21 delays the development of thymic lymphomas induced either by ataxia-telangiectasia mutated deficiency or by ionizing irradiation. Here, we extend these observations to the context of p53-deficient mice. The absence of p21 results in a significant extension of the lifespan of p53-null and p53-haploinsufficient mice, and this effect can be attributed exclusively to a decrease in the incidence of spontaneous thymic lymphomas. Specifically, despite the occurrence of a variety of tumor types in the context of p53 deficiency, the only tumors that were significantly impaired by the absence of p21 were thymic lymphomas. Moreover, the absence of p21 also delays the incidence of radiation-induced thymic lymphomas in p53-deficient mice. Interestingly, p21-deficient lymphomas have a higher apoptotic rate than p21-proficient lymphomas, and this could be on the basis of the delayed incidence of thymic lymphomas in the absence of p21. Together, our results indicate that p21 plays an oncogenic role restricted to thymic lymphomas that is mechanistically independent of p53 and associated to a lower tumor apoptotic rate.
The cell cycle inhibitor p21
Waf1/Cip1 binds and inactivates cyclin-dependent kinases and it is a critical mediator of p53-induced cell-cycle arrest (el-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . The analysis of p21-deficient mice (Brugarolas et al., 1995; Deng et al., 1995) has provided solid genetic evidence for the tumor suppressor activity of p21. Specifically, p21-null mice develop tumors spontaneously (Martin-Caballero et al., 2001) and show increased susceptibility to various carcinogenic treatments (Philipp et al., 1999; Topley et al., 1999; Weinberg et al., 1999; Jackson et al., 2002 Jackson et al., , 2003 Poole et al., 2004) ; moreover, p21 deficiency exacerbates the tumor-prone phenotype of mice with a variety of genetically engineered oncogenic alterations (Brugarolas et al., 1998; Adnane et al., 2000; Franklin et al., 2000; Yang et al., 2001; Bearss et al., 2002; Martin-Caballero et al., 2004; Yang et al., 2005) . Together, p21 deficiency contributes to the development of a wide range of tumor types in mice, which include skin, colon, intestine, pituitary, thyroid, mammary gland, salivary gland, connective tissue and histiocytic sarcomas (see above references).
In sharp contrast to above-mentioned general role of p21 in tumor suppression, thymic lymphomas are exceptional because they appear to be promoted, rather than suppressed, by p21. In particular, thymic lymphomas spontaneously developed by ataxia-telangiectasia mutated (ATM)-deficient mice are significantly decreased by the concomitant absence of p21 (Wang et al., 1997) . Also, radiation-induced thymic lymphomas are strikingly delayed in p21-deficient mice compared to p21-proficient mice (Martin-Caballero et al., 2001) . In both cases, it was found that lymphomas lacking p21 had higher apoptotic rates, suggesting that p21 could possess antiapoptotic activity. In this regard, there is an increasing number of reports indicating that p21 can be antiapoptotic, both in the context of a p53-triggered response as well as in the absence of p53 (reviewed in Gartel and Tyner, 2002) .
Here, we contribute additional evidence for the oncogenic role of p21 in thymic lymphoma, demonstrating its specificity to this tumor type, its independence from p53 and its association to a decreased apoptotic rate.
Cohorts of mice with or without p21 and in combination with a p53-heterozygote or p53-null genotype, all of them in a C57BL6 background, were monitored throughout their lives until moribund. In the case of C57BL6 p21-null mice (p53 þ / þ ;p21
), their average lifespan was 18 months and 70% of the animals presented tumors at the time of death. Mice deficient for p21 develop autoimmunity, but the penetrance and severity of this defect depends on the sex and the genetic background (Balomenos et al., 2000; Martin-Caballero et al., 2001; Salvador et al., 2002) . In the particular case of the C57BL6 genetic background, p21 deficiency also produces autoimmunity, but it results in mild renal defects with a modest sex influence (our unpublished observations). As for the genotypes relevant for the present work, namely, p53 heterozygote or p53 null in combination or not with p21 absence, the large majority of deaths were owing to tumors (>80%). More importantly, and similar to what has been reported for ATM-deficient mice (Wang et al., 1997) , absence of p21 produced a significant extension in the lifespan of both p53 þ /À mice ( Figure 1a ; from 11 to 19 months) and p53
À/À mice ( Figure 1b ; from 6 to 9 months). We conclude that the absence of p21 increases the latency of tumorigenesis in p53-deficient mice. Next, we investigated whether the effect of p21 deficiency was restricted to one or a few tumor types and, for this, we compared the incidence of each class of tumor in the different genotypes studied. Lymphomas were the most frequent and earliest arising malignancy in both p53-heterozygote and p53-null mice and, importantly, their incidence was decreased by the absence of p21 (Figure 2 ). In particular, in the case of p53
þ / þ mice, 44% of the tumors were lymphomas, of which the majority were T-cell lymphomas (70%; determined by CD3 positivity) and the rest B-cell lymphomas (30%; determined by B220 positivity). In the absence of p21, p53-heterozygote mice presented a Mice of genetic background C57BL6 (more than seven backcrosses) were housed under the same conditions, and were examined on a weekly basis. When moribund, mice were killed and subject to detailed necropsy followed by pathological analysis. The colony size for each genotype was: (p53 
Asterisks indicate that the difference between p21-deficient and -proficient mice was statistically significant (Fisher's exact test Po0.05). Thymic lymphomas were diagnosed by CD3-positive staining and always affected at least the thymus; B-cell lymphomas were diagnosed by B220-positive staining and affected several lymph nodes. In the case of p53 þ /À ;p21 þ / þ mice (black bars in the upper part of the figure), 31% of the tumors were thymic lymphomas and 13% B-cell lymphomas (total incidence of lymphomas: 44%). All the other lymphomas were T-cell lymphomas. Tumorigenic activity of p21 E De la Cueva et al significantly decreased incidence of lymphomas (12%), all of them corresponding to T-cell lymphomas. Regarding p53-null mice, the incidence of lymphomas also decreased in the absence of p21 (from 71 to 44%), being all the lymphomas of thymic origin (as determined by CD3 positivity) regardless of the status of p21. The incidence of other tumor types was similar, or more prominent, in p21-null mice compared to mice with functional p21. The histological features of the various tumor types were indistinguishable in the different genotypes (examples of the most common tumors are shown in Figures 2b-e) . In the particular case of histiocytic sarcomas, their incidence in p21 À/À mice was remarkably higher than in p21 þ / þ mice, both in p53 heterozygosity and in p53 nullizygosity, suggesting that this particular tumor type is favored by the absence of p21. This possibility is supported by the fact that histiocytic sarcomas constitute the most frequent tumor in singly deficient p21-null mice (Martin-Caballero et al., 2001 ). In conclusion, the absence of p21 has a major impact in survival by specifically decreasing the incidence of thymic lymphomas produced by p53 deficiency.
Previously, we have reported that p21 facilitates the development of radiation-induced thymic lymphomas (Martin-Caballero et al., 2001) . We wondered whether this effect was independent of p53 and, therefore, we measured the susceptibility to radiation-induced thymic lymphoma of p53-null mice, in combination or not with p21 deficiency (Figure 3a) . Importantly, the absence of p21 resulted in a significant delay in the appearance of thymic lymphomas. This result indicates that the oncogenic role of p21 for radiation-induced thymic lymphomas is independent of p53.
There is mounting evidence indicating that p21 can inhibit apoptosis in a p53-independent manner (reviewed in Gartel and Tyner, 2002) . We wondered whether p21 could affect cellular survival in the thymus and/or in the thymic lymphomas. Mice of the relevant genotypes were whole-body irradiated (10 Gy) and the short-term induction of apoptosis was analysed 3 h after in the thymus. In agreement with previous reports (Lowe et al., 1993; Deng et al., 1995) , we observed a potent apoptotic response in the thymi of wild-type and p21-null mice, whereas the thymi of p53-null mice were essentially resistant to apoptosis (Figure 3b ). Interestingly, radiation-induced apoptosis was absent in doubly deficient p53
À/À mice, in a manner quantitatively indistinguishable from p53 À/À mice. This result indicates that p21, regardless of the status of p53, does not modify the short-term survival of irradiated thymocytes and, therefore, this response cannot account for the differential latency of radiation-induced thymic lymphomas observed between p21-proficient and p21-deficient mice.
In the case of thymic lymphomas spontaneously developed in ATM-deficient mice or induced by radiation, it has been reported that lymphomas in p21-deficient mice have a high apoptotic rate and this could explain their longer latency (Wang et al., 1997; MartinCaballero et al., 2001) . To analyse if this also applies in the absence of p53, we examined first whether lymphomas generated in p53-deficient mice express or not p21. As shown in Figure 4a , all the spontaneous lymphomas developed in p53-null mice retained similar levels of p21 comparable to normal thymus, whereas radiationinduced lymphomas presented variable levels of p21. The fact that p21 expression is homogenously maintained in p53-null thymic lymphomas is compatible with a role of p21 in the development of these malignancies. Then, we measured the apoptotic rate in spontaneous lymphomas from p53 Cs irradiator; Shepherd & Associates, CA, USA) at a rate of 1.14 Gy/min. All the mice, regardless of their genotype, died with advanced thymic lymphoma. The colony size for each genotype was: (p53
Mice (1 month old) were subjected to a single 10 Gy whole-body g-irradiation dose. After 3 h, thymi were extracted and apoptotic thymocytes (DNA content lower than 2n, see also Garcia-Cao et al., 2002) were counted in an analytic flow cytometer (FACSCalibur, Beckton Dickinson). Each value corresponds to the average and s.d. of at least two mice per genotype.
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had apoptotic values (measured by PARP cleavage) that were not statistically different (not shown). These results confirm that the presence of p21 decreases the apoptotic rate of thymic lymphomas and demonstrates that this effect is independent of p53. A number of mechanisms have been reported that could explain the p53-independent antiapoptotic activity of p21 (reviewed in Gartel and Tyner, 2002) , being particularly relevant in the ability of p21 to bind and inhibit caspase-3 (Suzuki et al., 1998; Suzuki et al., 1999) . In this manner, p21 provides survival activity to apoptosis induced by Fas receptor (Suzuki et al., 1998; Suzuki et al., 1999) . Moreover, p21 is also antiapoptotic when death is induced by TNF, and it does so in a p53-independent manner (Xu and El-Deiry, 2000) . According to our present results and previous reports (Wang et al., 1997; Martin-Caballero et al., 2001) , the prosurvival activity of p21 operates in established thymic lymphomas, but not in response to an acute DNA damage insult, such as ionizing radiation. Conceivably, thymic lymphomas are exposed to apoptotic signals that are different from those triggered by acute ionizing radiation in the normal thymus. The presence of p21 in the established lymphomas could provide a survival advantage, perhaps to TNF-or Fas-triggered apoptosis, that would translate in an earlier onset and faster growth rate of the lymphomas.
In summary, our results provide additional genetic evidence for a tumorigenic activity of p21 specifically restricted to thymic lymphomas. This oncogenic activity does not require the presence of p53, and it is associated to a low apoptotic rate. It is relevant to emphasize that the tumorigenic effect of p21 on thymic lymphomas appears exceptional when compared with the large variety of other tumor types for which there is evidence for a tumor suppressor role of p21 (skin, colon, intestine, pituitary, thyroid, mammary gland, salivary gland, and connective tissue; for references, see introductory paragraph). In the case of B-cell malignancies, currently available evidence indicates that p21 is neutral for this type of tumors in the context of Myc-transgenic mice (Martins and Berns, 2002) or Ink4a/Arf-deficient mice (Martin-Caballero et al., 2004) . However, it cannot be excluded that the tumorigenic activity of p21 studied here in thymic lymphomas could also operate in tumor types not yet analysed. Tumorigenic activity of p21 E De la Cueva et al
